Clinical ReportsPrognostic significance of lactate dehydrogenase in cabazitaxel chemotherapy for castration-resistant prostate cancer a multi-institutional studyShiota, Masakia; Nakamura, Motonobub; Yokomizo, Akirac; Tomoda, Toshihisad; Sakamoto, Naotakae; Seki, Narihitof; Hasegawa, Shujig; Yunoki, Takakazuh; Harano, Masahikoi; Kuroiwa, Kentaroj; Eto, MasatoshiaAuthor Information aDepartment of Urology, Graduate School of Medical Sciences, Kyushu University bDepartment of Urology, National Hospital Organization Kyushu Cancer Center cDivision of Urology, Harasanshin Hospital, Fukuoka dDepartment of Urology, Oita Prefectural Hospital, Oita eDepartment of Urology, National Hospital Organization Kyushu Medical Center fDepartment of Urology, Kyushu Central Hospital, Fukuoka gDepartment of Urology, Kitakyushu Municipal Medical Center, Kitakyushu hDepartment of Urology, Japanese Red Cross Fukuoka Hospital, Fukuoka iDepartment of Urology, JCHO Kyushu Hospital, Kitakyushu jDepartment of Urology, Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan Received 16 August 2019 Revised form accepted 3 December 2019 Correspondence to Masaki Shiota, MD, PhD, Department of Urology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan, Tel: +81 92 642 5603; fax: +81 92 642 5618; e-mail: email@example.com Anti-Cancer Drugs: March 2020 - Volume 31 - Issue 3 - p 298-303 doi: 10.1097/CAD.0000000000000884 Buy Metrics Abstract This multi-institutional study aimed to identify prognostic factors for cabazitaxel treatment of castration-resistant prostate cancer (CRPC). This study included 74 Japanese patients with CRPC who were treated with cabazitaxel between 2014 and 2017. Associations between clinicopathological factors including serum markers and progression-free survival (PFS) and overall survival (OS) were investigated. On multivariate analysis, high Gleason score [≥9 vs. ≤7; hazard ratio (HR), 95% confidence interval (CI): 2.00 (1.01–4.34); P = 0.047], presence of pain [HR, 95% CI: 2.02 (1.14–3.58); P = 0.016], and lactate dehydrogenase (LDH) level [HR, 95% CI: 47.31 (3.79–577.49); P = 0.0019] were significantly associated with PFS. Similarly, number of docetaxel cycles [HR, 95% CI: 0.050 (0.0037–0.45); P = 0.0057], performance status [≥2 vs. 0; HR, 95% CI: 5.07 (1.57–16.24); P < 0.0001], and LDH level [HR, 95% CI: 2946 (50–420994); P = 0.0001] were significantly associated with OS. This study showed that LDH level is robustly prognostic for both PFS and OS in cabazitaxel chemotherapy for CRPC. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.